PBAC's latest decision on Rotigotine: Not recommended (2008). Considered for Monotherapy or in combination with levodopa for the treatment of idiopathic Parkinson's disease from early stage to advanced disease.
PBAC outcome
Not recommended
2008
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2008
Submissions
1
2008 → 2008
Eligible population
Patients with idiopathic Parkinson's disease from early stage to advanced disease, treated with rotigotine as monotherapy or in combination with levodopa.
Therapy area
Neurology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Other
Pivotal trial size
1,661 patients
Key trials
SP506, SP512, SP513, SP515, SP650
Comparator
cabergoline
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis presented; no incremental cost-effectiveness ratio stated.
Why PBAC said no
Reasons cited in the latest PSD: comparison against levodopa in early Parkinson's disease not provided, claim of superior safety profile over cabergoline not substantiated, claimed cost offsets for monitoring safety of cabergoline unacceptable